ONC BeOne Medicines Ltd.
$346.51
BeOne Medicines Ltd. (ONC) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
Bearish
Selling ran elevated versus ONC's own trailing one-year pace, with 97% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
7 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
12
141 transactions
Purchases
$0
0 shares
Sales
$317.1M
988,752 shares
Net activity
-$317.1M
purchases less sales
How much of that selling was preplanned? 97% planned / 3% discretionary
10b5-1 plan sales
$308.9M
99 transactions · 948,614 shares
Discretionary sales
$8.2M
42 transactions · 40,138 shares
Largest single sale: $16.2M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Wang Xiaodong 8 fills | Director | Sell 10b5-1 | 38,287 | $349.10 | $13.4M | 23,535 −61.9% of holding | |
| Ball Titus B. | Principal Accounting Officer | Sell | 132 | $355.86 | $47.0K | None left | |
| Wu Xiaobin | President and COO | Sell 10b5-1 | 280 | $380.00 | $106.4K | None left | |
| OYLER JOHN 5 fills | Chief Executive Officer | Sell 10b5-1 | 54,892 | $358.15 | $19.7M | 52,912 −50.9% of holding | |
| OYLER JOHN 9 fills | Chief Executive Officer | Sell 10b5-1 | 70,907 | $361.90 | $25.7M | 112,104 −38.7% of holding | |
| Lee Chan Henry | SVP, General Counsel | Sell 10b5-1 | 2,666 | $360.00 | $959.8K | None left | |
| OYLER JOHN 10 fills | Chief Executive Officer | Sell 10b5-1 | 115,011 | $357.87 | $41.2M | 240,743 −32.3% of holding | |
| Rosenberg Aaron | Chief Financial Officer | Sell | 1,157 | $312.72 | $361.8K | None left | |
| Lee Chan Henry | SVP, General Counsel | Sell | 1,044 | $323.69 | $337.9K | None left | |
| Lee Chan Henry | SVP, General Counsel | Sell 10b5-1 | 1,669 | $325.00 | $542.4K | None left | |
| OYLER JOHN 5 fills | Chief Executive Officer | Sell 10b5-1 | 61,397 | $317.67 | $19.5M | 46,018 −57.2% of holding | |
| OYLER JOHN 9 fills | Chief Executive Officer | Sell 10b5-1 | 48,316 | $312.25 | $15.1M | 18,491 −72.3% of holding | |
| OYLER JOHN 9 fills | Chief Executive Officer | Sell 10b5-1 | 64,628 | $312.00 | $20.2M | 63,188 −50.6% of holding | |
| OYLER JOHN 12 fills | Chief Executive Officer | Sell 10b5-1 | 166,597 | $318.09 | $53.0M | 166,364 −50% of holding | |
| OYLER JOHN 5 fills | Chief Executive Officer | Sell 10b5-1 | 116,557 | $311.95 | $36.4M | 110,490 −51.3% of holding | |
| OYLER JOHN 6 fills | Chief Executive Officer | Sell 10b5-1 | 145,861 | $305.95 | $44.6M | 94,510 −60.7% of holding | |
| OYLER JOHN 7 fills | Chief Executive Officer | Sell 10b5-1 | 48,520 | $304.35 | $14.8M | 47,722 −50.4% of holding | |
| OYLER JOHN 8 fills | Chief Executive Officer | Sell 10b5-1 | 11,698 | $298.34 | $3.5M | 10,205 −53.4% of holding | |
| Lee Chan Henry | SVP, General Counsel | Sell 10b5-1 | 664 | $302.46 | $200.8K | None left | |
| OYLER JOHN 3 fills | Chief Executive Officer | Sell | 3,410 | $273.78 | $933.6K | 1,610 −67.9% of holding | |
| Wu Xiaobin | President and COO | Sell | 1,292 | $276.26 | $356.9K | None left | |
| Wang Lai | President, Global Head of R&D | Sell | 1,068 | $276.74 | $295.6K | None left | |
| OYLER JOHN 3 fills | Chief Executive Officer | Sell | 3,693 | $265.55 | $980.7K | 2,043 −64.4% of holding | |
| Wu Xiaobin | President and COO | Sell | 1,357 | $266.76 | $362.0K | None left | |
| Wang Lai | President, Global Head of R&D | Sell | 1,169 | $265.39 | $310.2K | None left | |
| Lee Chan Henry | SVP, General Counsel | Sell | 590 | $265.98 | $156.9K | None left | |
| OYLER JOHN 4 fills | Chief Executive Officer | Sell | 1,949 | $257.24 | $501.4K | 1,208 −61.7% of holding | |
| Wang Lai | President, Global Head of R&D | Sell | 756 | $261.00 | $197.3K | None left | |
| Wu Xiaobin | President and COO | Sell | 626 | $261.20 | $163.5K | None left | |
| Rosenberg Aaron | Chief Financial Officer | Sell | 631 | $257.74 | $162.6K | None left | |
| Lee Chan Henry | SVP, General Counsel | Sell | 428 | $257.63 | $110.3K | None left | |
| Ball Titus B. 2 fills | Principal Accounting Officer | Sell | 169 | $257.20 | $43.5K | 120 −58.5% of holding | |
| OYLER JOHN 2 fills | Chief Executive Officer | Sell | 4,940 | $270.56 | $1.3M | 1,120 −81.5% of holding | |
| Wu Xiaobin 2 fills | President and COO | Sell | 1,484 | $269.37 | $399.7K | 40 −97.4% of holding | |
| Wang Lai 2 fills | President, Global Head of R&D | Sell | 1,367 | $269.38 | $368.2K | 40 −97.2% of holding | |
| Lee Chan Henry 2 fills | SVP, General Counsel | Sell | 871 | $270.42 | $235.5K | 160 −84.5% of holding | |
| Ball Titus B. 2 fills | Principal Accounting Officer | Sell | 136 | $271.33 | $36.9K | 36 −79.1% of holding | |
| Yi Qingqing | Director | Sell | 235 | $279.13 | $65.6K | None left | |
| 4 fills | Sell | 10,998 | $23.82 | $262.0K | 145,326 −7% of holding | ||
| Dugan Margaret | Director | Sell | 212 | $309.60 | $65.6K | None left | |
| Sanders Corazon (Corsee) D. | Director | Sell | 212 | $309.59 | $65.6K | None left | |
| Riva Alessandro | Director | Sell | 212 | $309.51 | $65.6K | None left | |
| Lee Chan Henry | SVP, General Counsel | Sell 10b5-1 | 332 | $310.72 | $103.2K | None left | |
| Lee Chan Henry | SVP, General Counsel | Sell 10b5-1 | 332 | $311.59 | $103.4K | None left |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.